Pharmacoeconomic considerations in treating patients with acute leukaemia (Q33648362)

28 July 2017

1 reference

title

Pharmacoeconomic considerations in treating patients with acute leukaemia (English)

1 reference

28 July 2017

1 reference

Jønsson V

1

1 reference

28 July 2017

Hansen MM

series ordinal

2

1 reference

28 July 2017

Ljungman P

series ordinal

3

1 reference

28 July 2017

Kaasa S

series ordinal

4

1 reference

28 July 2017

publication date

1 February 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

15

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

167-178

1 reference

European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Costs and cost-minimisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

21 January 2018

Cost-utility analysis

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Quality of life in adult cancer patients treated with bone marrow transplantation--a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Knowing just how effective is treatment: implications for care of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Generalisation from phase III clinical trials: survival, quality of life, and health economics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

An overview of adjuvant therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199915020-00005

Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpat

21 January 2018

1 reference

12 December 2020

Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?

1 reference

12 December 2020

Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee

1 reference

12 December 2020

Planned progressive antimicrobial therapy in neutropenic patients

1 reference

12 December 2020

Improved outcome in adult B-cell acute lymphoblastic leukemia

1 reference

12 December 2020

Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the

1 reference

12 December 2020

The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group

1 reference

12 December 2020

Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party

1 reference

12 December 2020

High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial

1 reference

12 December 2020

Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study

1 reference

12 December 2020

EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA

1 reference

12 December 2020

Acute myeloid leukaemia in childhood: the costs and benefits of intensive treatment.

1 reference

12 December 2020

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

12 December 2020

Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy.

1 reference

12 December 2020

Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisat

1 reference

12 December 2020

Use of stem cell factor to mobilize hematopoietic progenitors

1 reference

12 December 2020

Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants

1 reference

12 December 2020

Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study.

1 reference

12 December 2020

10.2165/00019053-199915020-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1000137172

0 references

1 reference